Clinical trials: Epirubicin
Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization
CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC
This retrospective multicenter study aims to evaluate whether radiographic microvascular invasion (MVI) status can predict treatment response in patients with intermediate-stage hepatocellular carcinoma (HCC) receiving…
- Conditions
- Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI), Tyrosine Kinase Inhibitors
- Trial name
- NCT07449065
- Testing
- TKI, TACE
- Where
- China
- Volunteers
- 324 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Gastric Cancer
The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer
Taking into account the substantial doubts concerning the potential benefit of postoperative part in the perioperative chemotherapy regimen we designed a study assessing value of this approach in gastric cancer.
- Trial name
- STOPEROPCHEM (NCT01787539)
- Testing
- Postoperative Chemotherapy
- Where
- 2 sites in Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Lublin
Neoplasms, Breast
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer.
- Trial name
- INDUCT (NCT01220128)
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A, Aromatase inhibitor, 5-Fluorouracil
- Where
- 36 sites in United States, Belgium and 5 more
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005581
- Testing
- cyclophosphamide, epirubicin hydrochloride, fluorouracil
- Where
- 25 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Inflammatory Breast Cancer
Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
This phase II multicentre randomized open-label study will assess the safety and efficacy of Pembrolizumab in combination with standard chemotherapy in inflammatory breast cancer.
- Trial name
- PELICAN (NCT03515798)
- Testing
- Pembrolizumab Injection, neoadjuvant EC-paclitaxel chemotherapy
- Where
- 12 sites in France
- Volunteers
- 52 people
- Sponsor
- Institut Paoli-Calmettes
Breast Neoplasms
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
The goal of this multicenter, two-cohort, exploratory clinical trial is to evaluate patients with early stage hormone receptor-negative breast cancer receiving standard adjuvant chemotherapy after surgery.
- Trial name
- SMA-BC-002 (NCT05978648)
- Testing
- Trilaciclib, Epirubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 116 people
- Sponsor
- wang shusen
Peripheral T-cell Lymphoma
Linperlisib Combined With Chidamide in Patients With PTCL
The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT06421948
- Testing
- Linperlisib and chidamide, cyclophosphamide, doxorubicin/epirubicin, vincristine, and prednisone
- Where
- 6 sites in China
- Volunteers
- 134 people
- Sponsor
- Yanyan Liu
BTK Inhibitors, Histone Deacetylase Inhibitor
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
Zanubrutinib, as a new generation of BTK inhibitors, has shown more potent antitumor activity and lower adverse reactions than ibrutinib in head-to-head clinical studies, which make it a promising regimen for B cell lymphoma.
- Conditions
- BTK Inhibitors, Histone Deacetylase Inhibitor, Double Express Diffuse Large B-cell Lymphoma
- Trial name
- NCT06890585
- Testing
- ZCR-CHOP, R-CHOP
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Li Zhiming
Breast Cancer
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00288002
- Testing
- trastuzumab, capecitabine, cyclophosphamide
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer
The purpose of this study is to evaluate anti-cancer stem cell (CSC) activity (measured by the amount of Aldehyde dehydrogenase 1/ALDH1+ cells before and after treatment) of pre-operative bevacizumab in combination with…
- Trial name
- AVASTEM (NCT01190345)
- Testing
- bevacizumab, no bevacizumab
- Where
- 3 sites in France
- Volunteers
- 75 people
- Sponsor
- Institut Paoli-Calmettes
Breast Cancer
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive…
- Trial name
- APHINITY (NCT01358877)
- Testing
- 5-Fluorouracil, Carboplatin, Cyclophosphamide
- Where
- 546 sites in United States, Argentina and 40 more
- Volunteers
- 4,804 people
- Sponsor
- Hoffmann-La Roche
Esophageal Cancer, Gastric Cancer
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments.
- Trial name
- NCT00737438
- Testing
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, epirubicin hydrochloride, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping…
- Trial name
- PACT-15 (NCT01150630)
- Testing
- capecitabine, cisplatin, epirubicin
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- IRCCS San Raffaele
Breast Cancer
6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients
In low-risk node-negative breast cancer patients adjuvant chemotherapy should be spared. The identification of this subgroup can be based either on clinical and pathological or on tumour-biological criteria.
- Trial name
- NNBC3-Europe (NCT01222052)
- Testing
- 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
- Where
- Germany
- Volunteers
- 4,150 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Breast Cancer
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
This is a prospective, randomised phase III trial, to compare the efficacy and safety profiles of two types of adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) negative, node positive breast…
- Trial name
- NCT00129935
- Testing
- Docetaxel, Capecitabine, Epirubicin
- Where
- 58 sites in Spain
- Volunteers
- 1,384 people
- Sponsor
- Spanish Breast Cancer Research Group
CYP3A Phenotyping, CYP3A5 and MDR1 Genotyping
Study of Usefulness of Genotyping to Predict Docetaxel Exposure and Adverse Events
Twenty patients with verified high risk breast cancer will be included in the study. Patients will receive three cycles of docetaxel followed by three cycles of CEF for their adjuvant treatment.
- Conditions
- CYP3A Phenotyping, CYP3A5 and MDR1 Genotyping, Docetaxel Toxicity, Associations Between Genetic Data and Docetaxel Toxicity
- Trial name
- Docetaxel (NCT01110291)
- Testing
- docetaxel + CEF
- Where
- Finland
- Volunteers
- 20 people
- Sponsor
- University of Turku
Breast Cancer
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
The GALADON trial is a diagnostic and interventional study in which different molecular imaging methods as Positon Emission Tomography (PET), different kind of Magnetic Resonance Imaging - methods (MRI, DWI and DCE-MRI) will be…
- Trial name
- NCT01690325
- Testing
- Docetaxel, Trastuzumab, Bevacizumab
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Women's Cancer Study Group GmbH
Lymphoma, Non-Hodgkin;Hodgkin Disease
Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma
Anthracyclines were basic drugs in lymphoma treatment. However, their dose accumulation related cardiac toxicity limits their clinical application, especially adriamycin. Adriamycin has been gradually replaced by epirubicin.
- Trial name
- NCT02526823
- Testing
- R-CHOP/CHOPE or ABVD chemotherapy regimen, R-CDOP/CDOPE or DBVD chemotherapy regimen
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Shandong Provincial Hospital
Breast Cancer
Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in higher doses over a shorter period of time may kill more tumor cells and have fewer side effects.
- Trial name
- NCT00872625
- Testing
- cyclophosphamide, docetaxel, epirubicin hydrochloride
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Centre Antoine Lacassagne
TNBC - Triple-Negative Breast Cancer
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with…
- Trial name
- NCT05862064
- Testing
- epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Fudan University